Hyperthyroidism means the thyroid gland is producing too much hormone, making the body run faster than it should. In pregnancy, it is uncommon, affecting about 0.1 to 0.4 percent of pregnancies, but it matters because uncontrolled disease can disrupt maternal health, placental function, and fetal growth. The problem is not simply a low TSH result. It is a clinical condition that needs correct diagnosis and follow-up.

In Indian pregnancy practice, the commonest persistent cause is Graves disease. Graves is an autoimmune condition in which antibodies stimulate the thyroid gland and keep it overactive. Because these antibodies can cross the placenta, management is not only about the mother. It is also about reducing risks to the fetus and newborn.

Careful treatment usually leads to good outcomes. The aim is to control excess thyroid hormone with the lowest effective dose, monitor mother and baby regularly, and avoid both undertreatment and overtreatment. Joint obstetric and endocrine follow-up is often the safest approach.

Not every pregnant woman with a suppressed TSH has Graves disease. Gestational transient hyperthyroidism is driven by very high hCG levels in early pregnancy, especially with severe vomiting, twins, or molar pregnancy. It usually appears in the first trimester and improves by the second trimester as hCG falls.

Graves disease behaves differently. It is caused by thyroid-stimulating antibodies, often called TRAb, and tends to persist beyond the first trimester unless treated. Women may have a previous thyroid history, a goiter, eye signs, or ongoing symptoms even after severe nausea settles. TRAb testing is the main lab clue that supports Graves.

This distinction matters because transient gestational hyperthyroidism often needs supportive care rather than antithyroid drugs. Overtreating it can push thyroid levels too low. Graves disease, in contrast, usually needs medication and closer fetal surveillance.

Common symptoms include palpitations, heat intolerance, hand tremor, anxiety, sweating, frequent stools, and weight loss despite eating. Some women feel constantly restless or notice unusual fatigue because the heart is working harder. These symptoms can overlap with normal pregnancy changes, which is why patterns and severity matter.

Graves disease may also cause a visible goiter or eye signs such as staring appearance or bulging eyes. These clues are useful because they are less likely to come from ordinary pregnancy symptoms alone. A past history of thyroid disease, treatment, or relapse after stopping medicines also raises suspicion.

Persistent severe morning sickness can be another signal, especially when vomiting seems out of proportion or comes with a very low TSH and high T4. In that situation, doctors must separate Graves disease from hCG-related transient hyperthyroidism and also consider Hyperemesis Gravidarum in India: Severe Pregnancy Vomiting, Hospital Care and Recovery.

Poorly controlled hyperthyroidism increases the risk of miscarriage, preterm birth, pregnancy-induced hypertension, and preeclampsia. It can also worsen maternal weight loss, dehydration, and heart strain. Even when symptoms seem tolerable, uncontrolled thyroid hormone excess can still affect pregnancy outcomes.

For the baby, risks include fetal growth restriction, low birth weight, and rarely fetal or neonatal thyrotoxicosis if maternal TRAb levels are high. This is one reason antibody testing matters in Graves disease. The issue is not only the medicine. Uncontrolled disease itself can be more dangerous than treatment.

The most severe maternal complication is thyroid storm, a rare but life-threatening emergency marked by extreme overactivity, fever, severe tachycardia, vomiting, and agitation. Prompt treatment greatly reduces risk, so red-flag symptoms should never be watched at home for long.

The starting point is thyroid function testing. A strongly suppressed TSH, often below 0.1, with elevated free T4 or total T4 supports hyperthyroidism. In India, TSH and T4 testing commonly costs about Rs 300 to Rs 800 depending on the lab and city. Test interpretation should use pregnancy context, not non-pregnant assumptions.

TRAb antibody testing helps confirm Graves disease and estimate fetal risk. In Indian private labs such as Dr Lal and similar chains, the test is often around Rs 2000 to Rs 4000. Physical examination also matters. Doctors look for goiter, tremor, pulse rate, blood pressure, weight trend, and eye findings.

Ultrasound of the thyroid may help when gland structure needs review and usually costs around Rs 600 to Rs 1500. Radio-iodine scans are contraindicated in pregnancy and should not be done. Diagnosis is built from history, examination, labs, and pregnancy-safe imaging only.

In the first trimester, PTU, or propylthiouracil, is usually preferred because methimazole has a small but important association with specific birth defects when exposure happens early in organ formation. A common Indian starting dose for mild to moderate disease is about 100 to 150 mg a day, adjusted to severity and lab results.

From the second trimester onward, most specialists switch from PTU to methimazole because methimazole is effective and carries lower maternal liver toxicity risk. In India, methimazole or carbimazole-based options such as Neo-Mercazole are commonly used. The principle is to switch after organ formation while keeping hormone control steady.

Across all trimesters, the goal is the lowest effective dose. Doctors try to keep maternal T4 in the upper normal range, not low, because overtreatment can cause fetal hypothyroidism or goiter. Dose changes should follow labs and symptoms, not guesswork.

Treatment starts with the lowest dose that controls symptoms and brings T4 toward the upper normal range. PTU 100 to 150 mg daily is a common early-pregnancy starting range, while methimazole is often used later at 5 to 15 mg daily depending on disease activity. The exact dose varies with severity and prior treatment history.

Monitoring is usually monthly with TSH and T4, especially after starting therapy or changing dose. TSH often lags behind improvement, so dose decisions should not be based on TSH alone. The target is steady control without pushing the mother or fetus toward hypothyroidism.

In India, generic PTU often costs about Rs 150 to Rs 400 a month. Methimazole or Neo-Mercazole commonly costs around Rs 100 to Rs 300 a month. Regular lab monitoring adds to cost, but it is central to safe treatment and usually prevents bigger complications later.

Pregnancy with Graves disease should generally be treated as high risk, especially when diagnosis is new, symptoms are marked, TRAb is positive, or medication doses are changing. The safest setup is joint care between an obstetrician and an endocrinologist. This reduces delays in balancing maternal control with fetal safety.

In India, endocrinology and high-risk obstetric services are available at tertiary centers such as AIIMS, Apollo, and Fortis. A specialist consultation often ranges from about Rs 800 to Rs 3000 depending on city and hospital. This can be worthwhile when diagnosis is uncertain or complications are suspected.

Indian practice is usually aligned with ICMR, FOGSI, and Indian Thyroid Society or ITSI style guidance. The practical takeaway is simple: do not manage persistent pregnancy hyperthyroidism with isolated lab follow-up alone. Specialist review improves dosing decisions and escalation planning.

Beta-blockers are sometimes added for short-term symptom relief while antithyroid medication starts working. They are useful when palpitations, tremor, or severe adrenergic symptoms are distressing. Propranolol is the usual option, often around 20 to 40 mg a day in divided doses depending on symptom burden.

The rule is lowest dose for the shortest duration. Beta-blockers improve symptoms quickly, but they do not treat the thyroid cause itself. Once antithyroid drugs take effect, propranolol is usually reduced or stopped rather than continued routinely.

Atenolol is generally avoided in pregnancy because of a stronger association with fetal growth restriction. In India, propranolol brands such as Inderal are widely available and often cost about Rs 50 to Rs 150 a month, but they should still be used under doctor supervision.

Thyroid storm is rare, but it is a true obstetric and endocrine emergency. Warning signs include fever, marked agitation, severe vomiting, confusion, dehydration, and a very fast heart rate, often above 140. These symptoms can escalate quickly and should not be managed with home rest or phone advice alone.

In India, urgent transport through 108 ambulance services is the right move if thyroid storm is suspected. Hospital care usually means ICU-level monitoring, fluids, and rapid combination treatment. Maternal stabilization comes first because fetal safety depends on it.

Treatment commonly includes PTU, iodine after antithyroid therapy has started, a beta-blocker, and steroids, along with supportive care and treatment of triggers such as infection. The key point is speed. Delay can be life-threatening for both mother and baby.